N. R. Srinivas
Cadila Healthcare (India)(IN)Biocon (India)(IN)
Publications by Year
Research Areas
Pharmacogenetics and Drug Metabolism, Gastroesophageal reflux and treatments, Analytical Methods in Pharmaceuticals, Helicobacter pylori-related gastroenterology studies, Angiogenesis and VEGF in Cancer
Most-Cited Works
- → Baicalin, an emerging multi-therapeutic agent: pharmacodynamics, pharmacokinetics, and considerations from drug development perspectives(2010)129 cited
- → Quantitation of VEGFR2 (vascular endothelial growth factor receptor) inhibitors – review of assay methodologies and perspectives(2014)53 cited
- → ‘Open access’ generic method for continuous determination of major human CYP450 probe substrates/metabolites and its application in drug metabolism studies(2003)16 cited
- Effects of gender, age, and race on the pharmacokinetics of etoposide after intravenous administration of etoposide phosphate in cancer patients.(1996)
- → Pre-clinical assessment of DRF 4367, a novel COX-2 inhibitor: Evaluation of pharmacokinetics, absolute oral bioavailability and metabolism in mice and comparative inter-speciesin vitrometabolism(2005)8 cited
- → High-Performance Liquid Chromatographic - Ultraviolet Assay for the Simultaneous Quantitation of BMS-181101 and its Putative Hydroxy Metabolites in Rat and Monkey Plasma(1996)4 cited
- → Letter: vonoprazan, a long‐lasting acid suppressor of the gastric H+, K+‐ATPases with ‐ implications for renal H+, K+‐ATPases(2016)4 cited
- → A drug–drug interaction study of everolimus (an mTOR inhibitor) and JI-101, an orally active inhibitor of VEGF 2, PDGF, and EphB4 receptors, in patients with advanced urologic tumors.(2011)3 cited
- → Stereoselective Tissue Distribution of Ketolorac in Rats – Differential Uptake of Ketolorac Enantiomers in Certain Tissues(2015)2 cited
- → 400 Phase I study of JI-101, a novel oral tyrosine kinase inhibitor that selectively targets EphB4, VEGFR2, and PDGFRβ(2010)2 cited